首页 > 最新文献

Journal of Diabetes Investigation最新文献

英文 中文
Precision medicine in diabetes prediction: Exploring a subgroup-specific biomarker strategy for risk stratification. 糖尿病预测中的精准医学:探索用于风险分层的亚组特异性生物标志物策略。
IF 3.2 3区 医学 Pub Date : 2024-11-13 DOI: 10.1111/jdi.14311
I-Weng Yen, Szu-Chi Chen, Chia-Hung Lin, Kang-Chih Fan, Chung-Yi Yang, Chih-Yao Hsu, Chun-Heng Kuo, Mao-Shin Lin, Ya-Pin Lyu, Hsien-Chia Juan, Lin Heng-Huei, Hung-Yuan Li

Introduction: The early detection of high-risk individuals is crucial to delay and reduce the incidence of type 2 diabetes. In this study, we aimed to explore the performance of a novel subgroup-specific biomarker strategy in the prediction of incident diabetes.

Materials and methods: In the Taiwan Lifestyle Cohort Study, adult subjects without diabetes were included and followed for the incidence of diabetes in 2006-2019. The biomarkers measured included blood secretogranin III (SCG3), vascular adhesion protein-1 (VAP-1), fibrinogen-like protein 1 (FGL1), angiopoietin-like protein 6 (ANGPTL6), and angiopoietin-like protein 4 (ANGPTL4).

Results: Among the 1,287 subjects, 12.2% developed diabetes during a 6 year follow-up. Blood VAP-1 was significantly associated with incident diabetes in the overall population (HR = 0.724, P < 0.05), participants under 65 years old (HR = 0.685, P < 0.05), those with a BMI of ≥24 kg/m2 (HR = 0.673, P < 0.05), and females (HR = 0.635, P < 0.05). Blood ANGPTL6 was significantly correlated with incident diabetes in participants aged 65 and older (HR = 0.314, P < 0.05), and blood SCG3 was associated with incident diabetes in those with a BMI of <24 kg/m2 (HR = 1.296, P < 0.05). Two subgroup-specific biomarker strategies were developed. The gender and BMI-specific biomarker strategy, using traditional risk factors and blood SCG3 or VAP-1 in different subgroups, could improve prediction performance, especially the specificity and positive prediction value, compared with the whole-population strategy using only traditional risk factors or traditional risk factors plus blood VAP-1.

Conclusion: Gender- and BMI-specific biomarker strategy can improve the prediction of incident diabetes. A subgroup-specific biomarker strategy is a novel approach in the prediction of incident diabetes.

导言:早期发现高危人群对于延迟和降低 2 型糖尿病的发病率至关重要。在这项研究中,我们旨在探索一种新型亚组特异性生物标志物策略在预测糖尿病发病率方面的性能:在台湾生活方式队列研究(Taiwan Lifestyle Cohort Study)中,我们纳入了2006-2019年未患糖尿病的成年受试者,并对其糖尿病发病率进行了随访。测量的生物标记物包括血液泌泌素 III(SCG3)、血管粘附蛋白-1(VAP-1)、纤维蛋白原样蛋白 1(FGL1)、血管生成素样蛋白 6(ANGPTL6)和血管生成素样蛋白 4(ANGPTL4):在 1287 名受试者中,12.2% 的人在 6 年的随访期间患上了糖尿病。在总体人群中,血液中的 VAP-1 与糖尿病发病率明显相关(HR = 0.724,P 2(HR = 0.673,P 2(HR = 1.296,P 结论):性别和体重指数特异性生物标志物策略可改善对糖尿病发病的预测。亚组特异性生物标志物策略是预测糖尿病发病的一种新方法。
{"title":"Precision medicine in diabetes prediction: Exploring a subgroup-specific biomarker strategy for risk stratification.","authors":"I-Weng Yen, Szu-Chi Chen, Chia-Hung Lin, Kang-Chih Fan, Chung-Yi Yang, Chih-Yao Hsu, Chun-Heng Kuo, Mao-Shin Lin, Ya-Pin Lyu, Hsien-Chia Juan, Lin Heng-Huei, Hung-Yuan Li","doi":"10.1111/jdi.14311","DOIUrl":"https://doi.org/10.1111/jdi.14311","url":null,"abstract":"<p><strong>Introduction: </strong>The early detection of high-risk individuals is crucial to delay and reduce the incidence of type 2 diabetes. In this study, we aimed to explore the performance of a novel subgroup-specific biomarker strategy in the prediction of incident diabetes.</p><p><strong>Materials and methods: </strong>In the Taiwan Lifestyle Cohort Study, adult subjects without diabetes were included and followed for the incidence of diabetes in 2006-2019. The biomarkers measured included blood secretogranin III (SCG3), vascular adhesion protein-1 (VAP-1), fibrinogen-like protein 1 (FGL1), angiopoietin-like protein 6 (ANGPTL6), and angiopoietin-like protein 4 (ANGPTL4).</p><p><strong>Results: </strong>Among the 1,287 subjects, 12.2% developed diabetes during a 6 year follow-up. Blood VAP-1 was significantly associated with incident diabetes in the overall population (HR = 0.724, P < 0.05), participants under 65 years old (HR = 0.685, P < 0.05), those with a BMI of ≥24 kg/m<sup>2</sup> (HR = 0.673, P < 0.05), and females (HR = 0.635, P < 0.05). Blood ANGPTL6 was significantly correlated with incident diabetes in participants aged 65 and older (HR = 0.314, P < 0.05), and blood SCG3 was associated with incident diabetes in those with a BMI of <24 kg/m<sup>2</sup> (HR = 1.296, P < 0.05). Two subgroup-specific biomarker strategies were developed. The gender and BMI-specific biomarker strategy, using traditional risk factors and blood SCG3 or VAP-1 in different subgroups, could improve prediction performance, especially the specificity and positive prediction value, compared with the whole-population strategy using only traditional risk factors or traditional risk factors plus blood VAP-1.</p><p><strong>Conclusion: </strong>Gender- and BMI-specific biomarker strategy can improve the prediction of incident diabetes. A subgroup-specific biomarker strategy is a novel approach in the prediction of incident diabetes.</p>","PeriodicalId":190,"journal":{"name":"Journal of Diabetes Investigation","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142613189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A machine learning model for predicting worsening renal function using one-year time series data in patients with type 2 diabetes. 利用一年时间序列数据预测 2 型糖尿病患者肾功能恶化的机器学习模型。
IF 3.2 3区 医学 Pub Date : 2024-11-13 DOI: 10.1111/jdi.14309
Mari Watanabe, Shu Meguro, Kaiken Kimura, Michiaki Furukoshi, Tsuyoshi Masuda, Makoto Enomoto, Hiroshi Itoh

Background and aims: To prevent end-stage renal disease caused by diabetic kidney disease, we created a predictive model for high-risk patients using machine learning.

Methods and results: The reference point was the time at which each patient's estimated glomerular filtration rate (eGFR) first fell below 60 mL/min/1.73 m2. The input period spanned the reference point to 1 year prior. The primary endpoint was a 50% decrease in eGFR from the mean of the input period over the 3 year evaluation period. We created predictive models for patients' primary endpoints using time series data of various variables over the input period. Among 2,533 total patients, 1,409 had reference points, 31 had records for their input and evaluation periods and had reached their primary endpoints, and 317 patients had not. The area under the curve (AUC) of the predictive model peaked (0.81) when the minimum eGFR, the difference between maximum and minimum eGFR, and both maximum and minimum urinary protein values were included in the features.

Conclusion: The accuracy of prognosis prediction can be improved by considering the variable components of urinary protein and eGFR levels. This model will allow us to identify patients whose renal functions are relatively preserved with eGFR of more than 60 mL/min/1.73 m2 and are likely to benefit clinically from immediate treatment intensification.

背景和目的:为了预防糖尿病肾病引起的终末期肾病,我们利用机器学习创建了高危患者预测模型:为了预防糖尿病肾病导致的终末期肾病,我们利用机器学习建立了一个高危患者预测模型:参考点是每位患者的估计肾小球滤过率(eGFR)首次低于 60 mL/min/1.73 m2 的时间。输入期从参考点到一年前。主要终点是在 3 年评估期内,eGFR 从输入期平均值下降 50%。我们利用输入期内各种变量的时间序列数据创建了患者主要终点的预测模型。在 2,533 名患者中,1,409 名患者有参考点,31 名患者有输入期和评估期的记录并达到了主要终点,317 名患者没有达到主要终点。当最小 eGFR、最大和最小 eGFR 之差以及最大和最小尿蛋白值被纳入特征时,预测模型的曲线下面积(AUC)达到峰值(0.81):结论:考虑尿蛋白和 eGFR 水平的可变成分可提高预后预测的准确性。结论:考虑尿蛋白和 eGFR 水平的可变成分可提高预后预测的准确性,该模型可帮助我们识别 eGFR 超过 60 mL/min/1.73 m2 的肾功能相对保留的患者,这些患者有可能从立即加强治疗中获益。
{"title":"A machine learning model for predicting worsening renal function using one-year time series data in patients with type 2 diabetes.","authors":"Mari Watanabe, Shu Meguro, Kaiken Kimura, Michiaki Furukoshi, Tsuyoshi Masuda, Makoto Enomoto, Hiroshi Itoh","doi":"10.1111/jdi.14309","DOIUrl":"https://doi.org/10.1111/jdi.14309","url":null,"abstract":"<p><strong>Background and aims: </strong>To prevent end-stage renal disease caused by diabetic kidney disease, we created a predictive model for high-risk patients using machine learning.</p><p><strong>Methods and results: </strong>The reference point was the time at which each patient's estimated glomerular filtration rate (eGFR) first fell below 60 mL/min/1.73 m<sup>2</sup>. The input period spanned the reference point to 1 year prior. The primary endpoint was a 50% decrease in eGFR from the mean of the input period over the 3 year evaluation period. We created predictive models for patients' primary endpoints using time series data of various variables over the input period. Among 2,533 total patients, 1,409 had reference points, 31 had records for their input and evaluation periods and had reached their primary endpoints, and 317 patients had not. The area under the curve (AUC) of the predictive model peaked (0.81) when the minimum eGFR, the difference between maximum and minimum eGFR, and both maximum and minimum urinary protein values were included in the features.</p><p><strong>Conclusion: </strong>The accuracy of prognosis prediction can be improved by considering the variable components of urinary protein and eGFR levels. This model will allow us to identify patients whose renal functions are relatively preserved with eGFR of more than 60 mL/min/1.73 m<sup>2</sup> and are likely to benefit clinically from immediate treatment intensification.</p>","PeriodicalId":190,"journal":{"name":"Journal of Diabetes Investigation","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142613097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
One step closer to solving the mystery of the anti-inflammatory effects of glucagon-like peptide-1 receptor agonists. 距离解开胰高血糖素样肽-1 受体激动剂的抗炎作用之谜又近了一步。
IF 3.2 3区 医学 Pub Date : 2024-11-13 DOI: 10.1111/jdi.14346
Hirotaka Watada

Glucagon-like peptide-1 (GLP-1) receptor agonists are antidiabetic drugs that possess a suppressive effect on the progression of atherosclerosis, and it has been thought that their anti-inflammatory effect is involved in their effect, but the detailed mechanism was unknown. Recently, Ben Nasr and colleagues have proposed easily understood mechanism for the anti-inflammatory effect of GLP-1 receptor agonists. They discovered that some normal T cells express GLP-1 receptors on their cell membranes and showed that GLP-1 has an inhibitory effect on T-cell function.

胰高血糖素样肽-1(GLP-1)受体激动剂是一种抗糖尿病药物,对动脉粥样硬化的进展具有抑制作用,人们一直认为其抗炎作用与该药物的抗炎作用有关,但具体机制尚不清楚。最近,Ben Nasr 及其同事提出了易于理解的 GLP-1 受体激动剂抗炎作用机制。他们发现一些正常 T 细胞的细胞膜上表达 GLP-1 受体,并证明 GLP-1 对 T 细胞功能有抑制作用。
{"title":"One step closer to solving the mystery of the anti-inflammatory effects of glucagon-like peptide-1 receptor agonists.","authors":"Hirotaka Watada","doi":"10.1111/jdi.14346","DOIUrl":"https://doi.org/10.1111/jdi.14346","url":null,"abstract":"<p><p>Glucagon-like peptide-1 (GLP-1) receptor agonists are antidiabetic drugs that possess a suppressive effect on the progression of atherosclerosis, and it has been thought that their anti-inflammatory effect is involved in their effect, but the detailed mechanism was unknown. Recently, Ben Nasr and colleagues have proposed easily understood mechanism for the anti-inflammatory effect of GLP-1 receptor agonists. They discovered that some normal T cells express GLP-1 receptors on their cell membranes and showed that GLP-1 has an inhibitory effect on T-cell function.</p>","PeriodicalId":190,"journal":{"name":"Journal of Diabetes Investigation","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142613113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Practice guideline: Statement regarding treatment for suspected slowly progressive type 1 diabetes (SPIDDM; probable) cases (English version). 实践指南:关于疑似缓慢进展型 1 型糖尿病(SPIDDM;可能)病例治疗的声明(英文版)。
IF 3.2 3区 医学 Pub Date : 2024-11-12 DOI: 10.1111/jdi.14267
Akira Shimada, Eiji Kawasaki, Norio Abiru, Takuya Awata, Yoichi Oikawa, Haruhiko Osawa, Hiroshi Kajio, Junji Kozawa, Kazuma Takahashi, Daisuke Chujo, Shinsuke Noso, Tomoyasu Fukui, Junnosuke Miura, Kazuki Yasuda, Hisafumi Yasuda, Akihisa Imagawa, Hiroshi Ikegami

Insulin treatment should be introduced in patients with slowly progressive type 1 diabetes (SPIDDM; definite), according to the revised diagnostic criteria of SPIDDM (2023). In contrast, SPIDDM (probable) patients are in a non-insulin-dependent state; therefore, a more flexible treatment can be considered, although sulfonylurea agents should be avoided. Insulin treatment has been shown to maintain endogenous insulin secretion capacity in SPIDDM (probable); however, this does not mean that all SPIDDM (probable) patients should use insulin from the early phase. Dipeptidyl peptidase-4 inhibitors and biguanides might be the treatment of choice for SPIDDM (probable), but no evidence exists for other hypoglycemic agents. In any case, careful monitoring of the endogenous insulin secretion capacity should be carried out, and if a decrease in insulin secretion capacity is suspected, a change in treatment should be considered to prevent progression to an insulin-dependent state.

根据修订后的 SPIDDM 诊断标准(2023 年),缓慢进展型 1 型糖尿病(SPIDDM;确诊)患者应采用胰岛素治疗。相比之下,SPIDDM(可能)患者处于非胰岛素依赖状态,因此可以考虑更灵活的治疗方法,但应避免使用磺脲类药物。胰岛素治疗可维持 SPIDDM(可能)患者的内源性胰岛素分泌能力;但这并不意味着所有 SPIDDM(可能)患者都应从早期阶段开始使用胰岛素。二肽基肽酶-4 抑制剂和双胍类药物可能是治疗 SPIDDM(疑似)的首选药物,但目前尚无证据表明其他降糖药物也可用于治疗 SPIDDM(疑似)。无论如何,都应仔细监测内源性胰岛素分泌能力,如果怀疑胰岛素分泌能力下降,应考虑改变治疗方法,以防止发展为胰岛素依赖状态。
{"title":"Practice guideline: Statement regarding treatment for suspected slowly progressive type 1 diabetes (SPIDDM; probable) cases (English version).","authors":"Akira Shimada, Eiji Kawasaki, Norio Abiru, Takuya Awata, Yoichi Oikawa, Haruhiko Osawa, Hiroshi Kajio, Junji Kozawa, Kazuma Takahashi, Daisuke Chujo, Shinsuke Noso, Tomoyasu Fukui, Junnosuke Miura, Kazuki Yasuda, Hisafumi Yasuda, Akihisa Imagawa, Hiroshi Ikegami","doi":"10.1111/jdi.14267","DOIUrl":"https://doi.org/10.1111/jdi.14267","url":null,"abstract":"<p><p>Insulin treatment should be introduced in patients with slowly progressive type 1 diabetes (SPIDDM; definite), according to the revised diagnostic criteria of SPIDDM (2023). In contrast, SPIDDM (probable) patients are in a non-insulin-dependent state; therefore, a more flexible treatment can be considered, although sulfonylurea agents should be avoided. Insulin treatment has been shown to maintain endogenous insulin secretion capacity in SPIDDM (probable); however, this does not mean that all SPIDDM (probable) patients should use insulin from the early phase. Dipeptidyl peptidase-4 inhibitors and biguanides might be the treatment of choice for SPIDDM (probable), but no evidence exists for other hypoglycemic agents. In any case, careful monitoring of the endogenous insulin secretion capacity should be carried out, and if a decrease in insulin secretion capacity is suspected, a change in treatment should be considered to prevent progression to an insulin-dependent state.</p>","PeriodicalId":190,"journal":{"name":"Journal of Diabetes Investigation","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142613174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Deterioration in ankle reflex is associated with a reduced estimated glomerular filtration rate in patients with type 2 diabetes: A retrospective observational cohort study. 踝反射恶化与 2 型糖尿病患者估计肾小球滤过率降低有关:一项回顾性观察队列研究。
IF 3.2 3区 医学 Pub Date : 2024-11-12 DOI: 10.1111/jdi.14348
Taichi Muramatsu, Daisuke Yamamuro, Akifumi Kushiyama, Takako Kikuchi

Aims/introduction: We investigated the association between the ankle reflex and the estimated glomerular filtration rate (eGFR) in patients with type 2 diabetes.

Materials and methods: This was a single-center, retrospective, observational cohort study. A total of 1,387 patients who underwent an ankle reflex examination between January 2005 and December 2015 were included in the analysis for the primary outcome. The findings of the ankle reflex examination were classified into three groups: normal, decreased, or absent. The primary outcome was defined as the incidence of a 40% loss of eGFR from baseline. A survival time analysis using the Kaplan-Meier method and a regression analysis using a Cox proportional hazards model were conducted to evaluate the association between the ankle reflex test results and loss of eGFR.

Results: The ankle reflex test results were as follows: normal, n = 678 (48.9%); decreased, n = 270 (19.5%); and absent, n = 439 (31.6%) patients. The median follow-up period was 5.6 years in the observational period. In the univariate regression analysis, decreased and absent ankle reflexes were significantly associated with loss of eGFR. Moreover, decreased ankle reflex (hazard ratio: 1.83, 95% confidence interval: 1.16-2.87) and absent ankle reflex (hazard ratio: 2.57, 95% confidence interval: 1.76-3.76) were independently associated with loss of eGFR after adjusting for prognostic risk factors.

Conclusions: Decreased and absent ankle reflexes are closely and independently associated with loss of eGFR in patients with type 2 diabetes.

目的/简介:我们研究了 2 型糖尿病患者的踝反射与估计肾小球滤过率(eGFR)之间的关系:这是一项单中心、回顾性、观察性队列研究。共有 1387 名患者在 2005 年 1 月至 2015 年 12 月期间接受了踝关节反射检查,并纳入了主要结果的分析。踝关节反射检查结果分为三组:正常、减弱或缺失。主要结果定义为 eGFR 从基线下降 40% 的发生率。采用 Kaplan-Meier 法进行生存时间分析,并采用 Cox 比例危险模型进行回归分析,以评估踝关节反射检查结果与 eGFR 下降之间的关系:踝关节反射测试结果如下:正常,678 例(48.9%);降低,270 例(19.5%);无,439 例(31.6%)。观察期的中位随访时间为 5.6 年。在单变量回归分析中,踝反射减弱和消失与 eGFR 下降显著相关。此外,在调整预后风险因素后,踝反射减弱(危险比:1.83,95% 置信区间:1.16-2.87)和踝反射消失(危险比:2.57,95% 置信区间:1.76-3.76)与 eGFR 下降独立相关:结论:踝关节反射减弱和消失与 2 型糖尿病患者的 eGFR 下降密切相关。
{"title":"Deterioration in ankle reflex is associated with a reduced estimated glomerular filtration rate in patients with type 2 diabetes: A retrospective observational cohort study.","authors":"Taichi Muramatsu, Daisuke Yamamuro, Akifumi Kushiyama, Takako Kikuchi","doi":"10.1111/jdi.14348","DOIUrl":"https://doi.org/10.1111/jdi.14348","url":null,"abstract":"<p><strong>Aims/introduction: </strong>We investigated the association between the ankle reflex and the estimated glomerular filtration rate (eGFR) in patients with type 2 diabetes.</p><p><strong>Materials and methods: </strong>This was a single-center, retrospective, observational cohort study. A total of 1,387 patients who underwent an ankle reflex examination between January 2005 and December 2015 were included in the analysis for the primary outcome. The findings of the ankle reflex examination were classified into three groups: normal, decreased, or absent. The primary outcome was defined as the incidence of a 40% loss of eGFR from baseline. A survival time analysis using the Kaplan-Meier method and a regression analysis using a Cox proportional hazards model were conducted to evaluate the association between the ankle reflex test results and loss of eGFR.</p><p><strong>Results: </strong>The ankle reflex test results were as follows: normal, n = 678 (48.9%); decreased, n = 270 (19.5%); and absent, n = 439 (31.6%) patients. The median follow-up period was 5.6 years in the observational period. In the univariate regression analysis, decreased and absent ankle reflexes were significantly associated with loss of eGFR. Moreover, decreased ankle reflex (hazard ratio: 1.83, 95% confidence interval: 1.16-2.87) and absent ankle reflex (hazard ratio: 2.57, 95% confidence interval: 1.76-3.76) were independently associated with loss of eGFR after adjusting for prognostic risk factors.</p><p><strong>Conclusions: </strong>Decreased and absent ankle reflexes are closely and independently associated with loss of eGFR in patients with type 2 diabetes.</p>","PeriodicalId":190,"journal":{"name":"Journal of Diabetes Investigation","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142613105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effects of switching from MiniMed™ 640G to 770G on continuous glucose monitoring metrics and DTR-QOL scores: An observational study of Japanese people with type 1 diabetes mellitus. 从 MiniMed™ 640G 转换到 770G 对连续血糖监测指标和 DTR-QOL 评分的影响:对日本 1 型糖尿病患者的观察研究。
IF 3.2 3区 医学 Pub Date : 2024-11-08 DOI: 10.1111/jdi.14350
Toshiki Kogai, Junko Sato, Haruna Yasuda, Tatsuhiro Ayame, Azusa Ozaki, Eri Takagi, Mami Koshibu, Yuya Nishida, Fuki Ikeda, Hirotaka Watada

Aims/introduction: We evaluated the effect of the MiniMed™ 770G, an insulin pump using hybrid closed-loop technology, on blood glucose management and quality of life in Japanese people with type 1 diabetes.

Materials and methods: This was a 52-week, prospective, observational study. Fifty Japanese people with type 1 diabetes switched from the MiniMed™ 640G to 770G, and we analyzed the continuous glucose monitoring data of 24 subjects who used auto mode throughout the study. We also analyzed the scores of the Diabetes Therapy-Related Quality of Life questionnaire completed by 26 auto-mode users before and after the treatment change.

Results: The baseline time in range 70-180 mg/dL was 67.3 (54.8-78.4)%, with a significant improvement beginning 8 weeks after the switch and lasting until 52 weeks. The baseline time below range <70 mg/dL was 1.9 (0.6-3.6)%, with a significant increase at week 8; however, the mean value was less than 4% throughout the study period. On the other hand, the number of blood glucose measurements significantly increased. While there was no significant difference in the overall change in the total Diabetes Therapy-Related Quality of Life score, there was a significant decrease in the treatment satisfaction score.

Conclusions: Use of the MiniMed™ 770G improved continuous glucose monitoring metrics. However, treatment satisfaction decreased, probably due to the increased frequency of blood glucose monitoring necessary to maintain auto mode.

目的/简介:我们评估了采用混合闭环技术的胰岛素泵 MiniMed™ 770G 对日本 1 型糖尿病患者血糖管理和生活质量的影响:这是一项为期 52 周的前瞻性观察研究。50 名日本 1 型糖尿病患者从 MiniMed™ 640G 换到了 770G,我们分析了在整个研究期间使用自动模式的 24 名受试者的连续血糖监测数据。我们还分析了 26 名自动模式用户在治疗改变前后完成的糖尿病治疗相关生活质量问卷的得分:结果:基线时间在 70-180 mg/dL 范围内的比例为 67.3 (54.8-78.4)%,从转换治疗模式 8 周后开始显著改善,并持续到 52 周。低于血糖范围的基线时间使用 MiniMed™ 770G 改善了连续血糖监测指标。然而,治疗满意度却有所下降,这可能是由于为维持自动模式而增加了血糖监测频率。
{"title":"Effects of switching from MiniMed™ 640G to 770G on continuous glucose monitoring metrics and DTR-QOL scores: An observational study of Japanese people with type 1 diabetes mellitus.","authors":"Toshiki Kogai, Junko Sato, Haruna Yasuda, Tatsuhiro Ayame, Azusa Ozaki, Eri Takagi, Mami Koshibu, Yuya Nishida, Fuki Ikeda, Hirotaka Watada","doi":"10.1111/jdi.14350","DOIUrl":"https://doi.org/10.1111/jdi.14350","url":null,"abstract":"<p><strong>Aims/introduction: </strong>We evaluated the effect of the MiniMed™ 770G, an insulin pump using hybrid closed-loop technology, on blood glucose management and quality of life in Japanese people with type 1 diabetes.</p><p><strong>Materials and methods: </strong>This was a 52-week, prospective, observational study. Fifty Japanese people with type 1 diabetes switched from the MiniMed™ 640G to 770G, and we analyzed the continuous glucose monitoring data of 24 subjects who used auto mode throughout the study. We also analyzed the scores of the Diabetes Therapy-Related Quality of Life questionnaire completed by 26 auto-mode users before and after the treatment change.</p><p><strong>Results: </strong>The baseline time in range 70-180 mg/dL was 67.3 (54.8-78.4)%, with a significant improvement beginning 8 weeks after the switch and lasting until 52 weeks. The baseline time below range <70 mg/dL was 1.9 (0.6-3.6)%, with a significant increase at week 8; however, the mean value was less than 4% throughout the study period. On the other hand, the number of blood glucose measurements significantly increased. While there was no significant difference in the overall change in the total Diabetes Therapy-Related Quality of Life score, there was a significant decrease in the treatment satisfaction score.</p><p><strong>Conclusions: </strong>Use of the MiniMed™ 770G improved continuous glucose monitoring metrics. However, treatment satisfaction decreased, probably due to the increased frequency of blood glucose monitoring necessary to maintain auto mode.</p>","PeriodicalId":190,"journal":{"name":"Journal of Diabetes Investigation","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142602636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Investigating the correlation of hip circumference to cardiovascular disease and type-2 diabetes using Mendelian randomization. 利用孟德尔随机法研究臀围与心血管疾病和 2 型糖尿病的相关性。
IF 3.2 3区 医学 Pub Date : 2024-11-07 DOI: 10.1111/jdi.14344
Hongtao Liu, Zhaoyu Li, Su Yan, Shaopeng Ming

Objective: This study aimed to assess the correlation between hip circumference (HC) and the risk of cardiovascular disease (CVD) and type 2 diabetes mellitus using Mendelian randomization (MR) to overcome observational study limitations.

Design: MR analysis utilized genetic variation from the MR Base in a two-sample analysis. Three methods were employed: MR-Egger regression, weighted median estimator, and inverse variance weighting (IVW).

Setting: Data was acquired from MR Base, a platform summarizing genome-wide association study (GWAS) data for MR research.

Main outcome measures: Publicly available summary statistics datasets from GWAS meta-analyses were used, with HC and HC adjusted for body mass index (BMI) as exposures. Data for CVD and type 2 diabetes mellitus were obtained as outcomes.

Results: Results indicated a positive causal relationship between HC and CVD (IVW: P = 1.84e-07, OR: 1.37, 95% CI: 1.22-1.54) as well as type 2 diabetes mellitus (IVW: P = 0.04, OR: 1.62, 95% CI: 1.02-2.56), independent of BMI. However, HC after BMI adjustment showed no significant causal relationship with CVD (IVW: P = 0.05, OR: 1.09, 95% CI: 1.00-1.19) and exhibited a negative association with type 2 diabetes mellitus (IVW: P = 0.00, OR: 0.76, 95% CI: 0.66-0.88), suggesting a protective effect against type 2 diabetes mellitus.

Conclusions: After adjusting for BMI, adipose tissue concentrated in the hip region showed a protective effect against type 2 diabetes mellitus but not against CVD. These findings offer insights into diabetes prevention and treatment strategies, and may inform plastic surgery procedures. Further research is needed to validate these findings and explore underlying mechanisms.

研究目的本研究旨在利用孟德尔随机法(MR)评估臀围(HC)与心血管疾病(CVD)和 2 型糖尿病风险之间的相关性,以克服观察性研究的局限性:设计:MR 分析在双样本分析中利用了 MR 基地的遗传变异。采用了三种方法:MR-Egger回归法、加权中位数估计法和逆方差加权法(IVW):数据来自 MR Base,这是一个用于 MR 研究的全基因组关联研究(GWAS)数据汇总平台:使用GWAS荟萃分析的公开统计汇总数据集,以HC和HC调整体重指数(BMI)作为暴露。以心血管疾病和 2 型糖尿病的数据作为结果:结果表明,HC 与心血管疾病(IVW:P = 1.84e-07,OR:1.37,95% CI:1.22-1.54)和 2 型糖尿病(IVW:P = 0.04,OR:1.62,95% CI:1.02-2.56)之间存在正向因果关系,与体重指数无关。然而,调整体重指数后,HC 与心血管疾病无明显因果关系(IVW:P = 0.05,OR:1.09,95% CI:1.00-1.19),与 2 型糖尿病呈负相关(IVW:P = 0.00,OR:0.76,95% CI:0.66-0.88),表明对 2 型糖尿病有保护作用:结论:调整体重指数后,集中在臀部的脂肪组织对 2 型糖尿病有保护作用,但对心血管疾病没有保护作用。这些发现为糖尿病的预防和治疗策略提供了启示,并可为整形手术提供参考。还需要进一步的研究来验证这些发现并探索其背后的机制。
{"title":"Investigating the correlation of hip circumference to cardiovascular disease and type-2 diabetes using Mendelian randomization.","authors":"Hongtao Liu, Zhaoyu Li, Su Yan, Shaopeng Ming","doi":"10.1111/jdi.14344","DOIUrl":"https://doi.org/10.1111/jdi.14344","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to assess the correlation between hip circumference (HC) and the risk of cardiovascular disease (CVD) and type 2 diabetes mellitus using Mendelian randomization (MR) to overcome observational study limitations.</p><p><strong>Design: </strong>MR analysis utilized genetic variation from the MR Base in a two-sample analysis. Three methods were employed: MR-Egger regression, weighted median estimator, and inverse variance weighting (IVW).</p><p><strong>Setting: </strong>Data was acquired from MR Base, a platform summarizing genome-wide association study (GWAS) data for MR research.</p><p><strong>Main outcome measures: </strong>Publicly available summary statistics datasets from GWAS meta-analyses were used, with HC and HC adjusted for body mass index (BMI) as exposures. Data for CVD and type 2 diabetes mellitus were obtained as outcomes.</p><p><strong>Results: </strong>Results indicated a positive causal relationship between HC and CVD (IVW: P = 1.84e-07, OR: 1.37, 95% CI: 1.22-1.54) as well as type 2 diabetes mellitus (IVW: P = 0.04, OR: 1.62, 95% CI: 1.02-2.56), independent of BMI. However, HC after BMI adjustment showed no significant causal relationship with CVD (IVW: P = 0.05, OR: 1.09, 95% CI: 1.00-1.19) and exhibited a negative association with type 2 diabetes mellitus (IVW: P = 0.00, OR: 0.76, 95% CI: 0.66-0.88), suggesting a protective effect against type 2 diabetes mellitus.</p><p><strong>Conclusions: </strong>After adjusting for BMI, adipose tissue concentrated in the hip region showed a protective effect against type 2 diabetes mellitus but not against CVD. These findings offer insights into diabetes prevention and treatment strategies, and may inform plastic surgery procedures. Further research is needed to validate these findings and explore underlying mechanisms.</p>","PeriodicalId":190,"journal":{"name":"Journal of Diabetes Investigation","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142589940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
miR-155 promotes m6A modification of SOX2 mRNA through targeted regulation of HIF-1α and delays wound healing in diabetic foot ulcer in vitro models. miR-155 通过靶向调节 HIF-1α 促进 SOX2 mRNA 的 m6A 修饰,并延缓糖尿病足溃疡体外模型的伤口愈合。
IF 3.2 3区 医学 Pub Date : 2024-11-07 DOI: 10.1111/jdi.14327
Jiarui Peng, Hong Zhu, Bin Ruan, Zhisheng Duan, Mei Cao

Objective: Diabetic foot ulcers (DFU) are one of the most destructive complications of diabetes mellitus. The aim of this study was to link miR-155 and SOX2 with DFU to explore the regulation of wound healing by DFU and its potential mechanism.

Methods: Human keratinocytes (HaCaT) were induced with advanced glycation end products (AGEs) to construct DFU models in vitro. AGE-induced HaCaT cells were subjected to CCK-8 assays, flow cytometry, and wound healing assays to evaluate cell proliferation, apoptosis, and migration capacity, respectively. RT-qPCR and Western blotting were used to determine gene and protein expression levels, respectively. N6-methyladenosine (M6A) levels in total RNA were assessed using an M6A methylation quantification kit.

Results: Our results suggested that the inhibition of miR-155 promoted wound healing in an in vitro DFU model, while the knockdown of HIF-1α reversed this process, and that HIF-1α was a target protein of miR-155. In addition, knockdown of HIF-1α promoted the m6A level of SOX2 mRNA, inhibited the expression of SOX2, and inhibited the activation of the EGFR/MEK/ERK signaling pathway, thus inhibiting the proliferation and migration of HaCaT cells and promoting the apoptosis of HaCaT cells, while overexpression of SOX2 reversed this effect. We also found that METTL3 knockdown had the opposite effect of HIF-1α knockdown.

Conclusions: Inhibition of miR-155 promoted the expression of HIF-1α and attenuated the m6A modification of SOX2 mRNA, thereby promoting the expression of SOX2 and activating the downstream EGFR/MEK/ERK signaling pathway to promote wound healing in an in vitro DFU model.

目的:糖尿病足溃疡(DFU)是糖尿病最具破坏性的并发症之一:糖尿病足溃疡(DFU)是糖尿病最具破坏性的并发症之一。本研究旨在将 miR-155 和 SOX2 与 DFU 联系起来,探讨 DFU 对伤口愈合的调控及其潜在机制。方法:用高级糖化终产物(AGEs)诱导人角质形成细胞(HaCaT),在体外构建 DFU 模型。对 AGE 诱导的 HaCaT 细胞进行 CCK-8 试验、流式细胞术和伤口愈合试验,分别评估细胞增殖、凋亡和迁移能力。RT-qPCR 和 Western 印迹技术分别用于测定基因和蛋白质的表达水平。使用 M6A 甲基化定量试剂盒评估了总 RNA 中的 N6-甲基腺苷(M6A)水平:结果:我们的研究结果表明,在体外 DFU 模型中,抑制 miR-155 能促进伤口愈合,而敲除 HIF-1α 则能逆转这一过程,HIF-1α 是 miR-155 的靶蛋白。此外,HIF-1α的敲除促进了SOX2 mRNA的m6A水平,抑制了SOX2的表达,抑制了表皮生长因子受体/MEK/ERK信号通路的激活,从而抑制了HaCaT细胞的增殖和迁移,促进了HaCaT细胞的凋亡,而过表达SOX2则逆转了这一效应。我们还发现,METTL3敲除与HIF-1α敲除的效果相反:结论:在体外DFU模型中,抑制miR-155可促进HIF-1α的表达,减轻SOX2 mRNA的m6A修饰,从而促进SOX2的表达并激活下游的表皮生长因子受体/MEK/ERK信号通路,促进伤口愈合。
{"title":"miR-155 promotes m6A modification of SOX2 mRNA through targeted regulation of HIF-1α and delays wound healing in diabetic foot ulcer in vitro models.","authors":"Jiarui Peng, Hong Zhu, Bin Ruan, Zhisheng Duan, Mei Cao","doi":"10.1111/jdi.14327","DOIUrl":"https://doi.org/10.1111/jdi.14327","url":null,"abstract":"<p><strong>Objective: </strong>Diabetic foot ulcers (DFU) are one of the most destructive complications of diabetes mellitus. The aim of this study was to link miR-155 and SOX2 with DFU to explore the regulation of wound healing by DFU and its potential mechanism.</p><p><strong>Methods: </strong>Human keratinocytes (HaCaT) were induced with advanced glycation end products (AGEs) to construct DFU models in vitro. AGE-induced HaCaT cells were subjected to CCK-8 assays, flow cytometry, and wound healing assays to evaluate cell proliferation, apoptosis, and migration capacity, respectively. RT-qPCR and Western blotting were used to determine gene and protein expression levels, respectively. N6-methyladenosine (M6A) levels in total RNA were assessed using an M6A methylation quantification kit.</p><p><strong>Results: </strong>Our results suggested that the inhibition of miR-155 promoted wound healing in an in vitro DFU model, while the knockdown of HIF-1α reversed this process, and that HIF-1α was a target protein of miR-155. In addition, knockdown of HIF-1α promoted the m6A level of SOX2 mRNA, inhibited the expression of SOX2, and inhibited the activation of the EGFR/MEK/ERK signaling pathway, thus inhibiting the proliferation and migration of HaCaT cells and promoting the apoptosis of HaCaT cells, while overexpression of SOX2 reversed this effect. We also found that METTL3 knockdown had the opposite effect of HIF-1α knockdown.</p><p><strong>Conclusions: </strong>Inhibition of miR-155 promoted the expression of HIF-1α and attenuated the m6A modification of SOX2 mRNA, thereby promoting the expression of SOX2 and activating the downstream EGFR/MEK/ERK signaling pathway to promote wound healing in an in vitro DFU model.</p>","PeriodicalId":190,"journal":{"name":"Journal of Diabetes Investigation","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142602643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
LX9211, a rising star for relieving of diabetic peripheral neuropathic pain. LX9211,缓解糖尿病周围神经痛的后起之秀。
IF 3.2 3区 医学 Pub Date : 2024-11-07 DOI: 10.1111/jdi.14342
Chia-Chin Lee, Fu-Shun Ko, Fu-Shun Yen, Chii-Min Hwu

In a multicenter trial, LX9211 significantly reduced pain in diabetic peripheral neuropathy (DPN) patients, with the 10 mg dose showing notable relief by the first week. Although the higher dose was less effective, side effects like dizziness and nausea were generally mild. These findings highlight the importance of exploring both pharmaceutical and natural treatments, such as flavonoids, for managing DPN.

在一项多中心试验中,LX9211 能明显减轻糖尿病周围神经病变(DPN)患者的疼痛,10 毫克剂量在第一周就有明显缓解。虽然高剂量的疗效较差,但头晕和恶心等副作用一般较轻。这些发现凸显了探索黄酮类化合物等药物和天然疗法治疗 DPN 的重要性。
{"title":"LX9211, a rising star for relieving of diabetic peripheral neuropathic pain.","authors":"Chia-Chin Lee, Fu-Shun Ko, Fu-Shun Yen, Chii-Min Hwu","doi":"10.1111/jdi.14342","DOIUrl":"https://doi.org/10.1111/jdi.14342","url":null,"abstract":"<p><p>In a multicenter trial, LX9211 significantly reduced pain in diabetic peripheral neuropathy (DPN) patients, with the 10 mg dose showing notable relief by the first week. Although the higher dose was less effective, side effects like dizziness and nausea were generally mild. These findings highlight the importance of exploring both pharmaceutical and natural treatments, such as flavonoids, for managing DPN.</p>","PeriodicalId":190,"journal":{"name":"Journal of Diabetes Investigation","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142602638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Monocyte-lymphocyte ratio predicts cardiovascular diseases death in individuals with type 2 diabetes. 单核细胞-淋巴细胞比率可预测 2 型糖尿病患者死于心血管疾病的风险。
IF 3.2 3区 医学 Pub Date : 2024-11-06 DOI: 10.1111/jdi.14329
Han Li, Yixuan Li, Wenwen Guo, Xinwei Liu, Yuhao Wang, Tianshu Zeng, Wen Kong

Purpose: Previous studies have shown higher cardiovascular mortality risk with higher monocyte-lymphocyte ratio levels in general population. However, the levels of oxidative stress in individuals with type 2 diabetes are higher than those in the general population, which may affect the link between monocyte-to-lymphocyte ratio and cardiovascular disease deaths. And the association between the monocyte-to-lymphocyte ratio and mortality risk in people with type 2 diabetes still be unknown. This study aimed to investigate the prognostic significance of monocyte-to-lymphocyte ratio in type 2 diabetes.

Methods: This analysis involved 2,954 individuals with type 2 diabetes from the National Health and Nutrition Examination Survey 1999-2010. The National Death Index records through December 31, 2019, was used to determine all-cause and cardiovascular mortality. The prognostic roles were determined using Cox regression models, restricted cubic spline analysis, and time-dependent receiver operating characteristic curve analysis.

Results: During an average follow-up period of 12.4 years, a total of 1,007 deaths occurred, while 252 were due to cardiovascular disease. An elevated monocyte-to-lymphocyte ratio level exhibited a significant dose-response relationship with an increased risk of all-cause mortality (1.34 [95% CI 1.12, 1.60] for all-cause mortality [P trend = 0.001]). The multivariable-adjusted HR was 1.81 (95% CI 1.25, 2.63) (P trend = 0.001) for cardiovascular mortality indicating a U-shaped relationship (P nonlinear = 0.013).

Conclusions: The results of this study indicate a U-shaped relationship between the monocyte-to-lymphocyte ratio and cardiovascular mortality in individuals with diabetes. Both very low and high monocyte-to-lymphocyte ratio monocyte-to-lymphocyte ratio values were found to be associated with increased cardiovascular mortality risk.

目的:以往的研究表明,普通人群中单核细胞-淋巴细胞比率水平越高,心血管疾病死亡风险越高。然而,2 型糖尿病患者的氧化应激水平高于普通人群,这可能会影响单核细胞-淋巴细胞比率与心血管疾病死亡之间的联系。而2型糖尿病患者的单核细胞与淋巴细胞比值与死亡风险之间的关系仍然未知。本研究旨在探讨 2 型糖尿病患者单核细胞与淋巴细胞比值的预后意义:本分析涉及 2 954 名 2 型糖尿病患者,这些患者来自 1999-2010 年全国健康与营养调查(National Health and Nutrition Examination Survey 1999-2010)。使用截至 2019 年 12 月 31 日的国家死亡指数记录来确定全因死亡率和心血管死亡率。使用 Cox 回归模型、限制性三次样条分析和时间依赖性接收器操作特征曲线分析确定预后作用:在平均 12.4 年的随访期内,共有 1,007 人死亡,其中 252 人死于心血管疾病。单核细胞与淋巴细胞比值升高与全因死亡风险增加呈显著的剂量反应关系(全因死亡风险为 1.34 [95% CI 1.12, 1.60] [P 趋势 = 0.001])。心血管疾病死亡率的多变量调整 HR 为 1.81(95% CI 1.25,2.63)(P 趋势 = 0.001),显示出 U 型关系(P 非线性 = 0.013):本研究结果表明,单核细胞与淋巴细胞比值与糖尿病患者的心血管死亡率呈 U 型关系。单核细胞与淋巴细胞比值极低和极高都与心血管死亡风险增加有关。
{"title":"Monocyte-lymphocyte ratio predicts cardiovascular diseases death in individuals with type 2 diabetes.","authors":"Han Li, Yixuan Li, Wenwen Guo, Xinwei Liu, Yuhao Wang, Tianshu Zeng, Wen Kong","doi":"10.1111/jdi.14329","DOIUrl":"https://doi.org/10.1111/jdi.14329","url":null,"abstract":"<p><strong>Purpose: </strong>Previous studies have shown higher cardiovascular mortality risk with higher monocyte-lymphocyte ratio levels in general population. However, the levels of oxidative stress in individuals with type 2 diabetes are higher than those in the general population, which may affect the link between monocyte-to-lymphocyte ratio and cardiovascular disease deaths. And the association between the monocyte-to-lymphocyte ratio and mortality risk in people with type 2 diabetes still be unknown. This study aimed to investigate the prognostic significance of monocyte-to-lymphocyte ratio in type 2 diabetes.</p><p><strong>Methods: </strong>This analysis involved 2,954 individuals with type 2 diabetes from the National Health and Nutrition Examination Survey 1999-2010. The National Death Index records through December 31, 2019, was used to determine all-cause and cardiovascular mortality. The prognostic roles were determined using Cox regression models, restricted cubic spline analysis, and time-dependent receiver operating characteristic curve analysis.</p><p><strong>Results: </strong>During an average follow-up period of 12.4 years, a total of 1,007 deaths occurred, while 252 were due to cardiovascular disease. An elevated monocyte-to-lymphocyte ratio level exhibited a significant dose-response relationship with an increased risk of all-cause mortality (1.34 [95% CI 1.12, 1.60] for all-cause mortality [P trend = 0.001]). The multivariable-adjusted HR was 1.81 (95% CI 1.25, 2.63) (P trend = 0.001) for cardiovascular mortality indicating a U-shaped relationship (P nonlinear = 0.013).</p><p><strong>Conclusions: </strong>The results of this study indicate a U-shaped relationship between the monocyte-to-lymphocyte ratio and cardiovascular mortality in individuals with diabetes. Both very low and high monocyte-to-lymphocyte ratio monocyte-to-lymphocyte ratio values were found to be associated with increased cardiovascular mortality risk.</p>","PeriodicalId":190,"journal":{"name":"Journal of Diabetes Investigation","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142581520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Diabetes Investigation
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1